Gene therapy progress and prospects: Transcription regulatory systems

Gene Therapy

Volumn 11, Issue 8, 2004, Pages 649-657

  Toniatti, Carlo ^a   Bujard, H ^b   Cortese, R ^a   Ciliberto, G ^a  

^a IRBM   (Italy)

^b ZMBH   (Germany)

Author keywords

Inducible transcription; Ligand dependent switches; Transcriptional regulation

Indexed keywords

4 HYDROXYTAMOXIFEN; AP 21967; AP 22565; DIHYDROFOLATE REDUCTASE; DNA BINDING PROTEIN; DOXYCYCLINE; ECDYSONE; ERYTHROPOIETIN; ESTRADIOL; ETOPOSIDE; FK 506 BINDING PROTEIN; GENE PRODUCT; GENESWITCH; HUMAN GROWTH HORMONE; HYBRID PROTEIN; HYDRAZINE DERIVATIVE; METHOTREXATE; MIFEPRISTONE; PLASMID DNA; PONASTERONE A; RAPAMYCIN; RAPAMYCIN DERIVATIVE; STEROID HORMONE; TACROLIMUS; TAMOXIFEN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR GAL4; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR; ZINC FINGER PROTEIN;

ANTIBIOTIC RESISTANCE; DISEASE COURSE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SPECIFICITY; ENDOMETRIUM CANCER; GENE CONTROL; GENE EXPRESSION SYSTEM; GENE THERAPY; HOT FLUSH; HUMAN; IMMUNOGENICITY; NONHUMAN; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; TRANSCRIPTION REGULATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANTI-BACTERIAL AGENTS; GENE EXPRESSION REGULATION; GENE THERAPY; GENES, BACTERIAL; GENES, REGULATOR; GENES, SWITCH; HUMANS; LIGANDS; TRANSCRIPTION, GENETIC; TRANSGENES;

EID: 1942537842     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302251     Document Type: Review

References (70)

1. Baron U, Bujard H. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol 2000; 327: 401-421.
2. Urlinger S et al. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 2000; 97: 7963-7968.
3. Lamartina S et al. Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators. Hum Gene Ther 2002; 13: 199-210.
4. Aurisicchio L et al. Regulated and prolonged expression of mIFN(alpha) in immunocompetent mice mediated by a helper-dependent adenovirus vector. Gene Therapy 2001; 8: 1817-1825.
5. s-M2 shows a tight control of gene expression in vitro and in vivo. Gene Therapy 2003; 10: 459-466.
6. Salucci V et al. Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. Gene Therapy 2002; 9: 1415-1421.
7. McGee LH et al. Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina. Mol Ther 2001; 3: 688-696.
8. Rendahl KG et al. Tightly regulated long-term erythropoietin expression in vivo using tet-inducible recombinant adeno-associated viral vectors. Hum Gene Ther 2002; 13: 335-342.
9. Lamartina S et al. Construction of an rtTA 2s-M2/tTSkid-based transcription regulatory switch which displays no basal activity, great inducibility and high responsiveness to Doxycycline in mice and non-human primates. Mol Ther 2003; 7: 271-280.
10. Mizuguchi H et al. Tigth positive regulation of transgene expression by a single adenovirus vector containing the rtTA and tTS expression cassettes in separate genome regions. Hum Gene Ther 2003; 14: 1265-1277.
11. Favre D et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol 2002; 76: 11605-11611.
12. Latta-Mahieu M et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther 2002; 13: 1611-1620.
13. Klein NC, Cunha BA. New uses of older antibiotics. Med Clin North Am 2001; 85: 125-132.
14. Krueger et al. Single-chain Tet transregulators. Nucleic Acid Res 2003; 31: 3050-3056.
15. Pollock R, Clackson T. Dimerizer-regulated gene expression. Curr Opin Biotechnol 2002; 13: 459-467.
16. Xu Z-L, Mizuguchi H, Mayumi T, Hayakawa T. Regulated gene expression from adenovirus vectors: a systematic comparison of various inducible systems. Gene 2003; 309: 145-151.
17. Pollock R et al. Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector. Proc Natl Acad Sci USA 2000; 97: 13221-13226.
18. Auricchio A et al. Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer. Gene Therapy 2002; 9: 963-971.
19. Auricchio A et al. Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther 2002; 6: 238-242.
20. Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother 2001; 2: 1903-1917.
21. Chong H et al. A system for small-molecule control of conditionally replication-competent adenoviral vectors. Mol Ther 2002; 5: 195-203.
22. Clemons P et al. Synthesis of calcineurin-resistant derivatives of FK506 and selection of compensatory receptors. Chem Biol 2002; 9: 49-61.
23. Althoff E, Cornish VW. A bacterial small-molecule three-hybrid system. Angew Chem Int Ed Eng 2002; 41: 2327-2330.
24. Lin H, Abida WM, Sauer RT, Cornish VW. Dexamethasone-methotrexate: an efficient chemical inducer of dimerization in vivo. Am Chem Soc 2000; 122: 4247-4248.
25. Leonhardt SA, Edwards DP. Mechanism of action of progesterone antagonists. Exp Biol Med 2002; 227: 969-980.
26. Nordstrom JL. Antiprogestin-controllable transgene regulation in vivo. Curr Opin Biotechnol 2002; 13: 453-458.
27. Abruzzese RV et al. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Mol Ther 2000; 2: 276-287.
28. Ye X et al. Ligand-inducible transgene regulation for gene therapy. Methods Enzymol 2002; 346: 551-561.
29. Terada Y et al. Ligand-regulatable erythropoietin production by plasmid injection and in vivo electroporation. Kidney Int 2002; 64: 1966-1976.
30. Nordstrom JL. The antiprogestin-dependent GeneSwitch® system for regulated gene therapy. Steroids 2003; 68: 1085-1094.
31. Draghia-Akli R et al. Enhanced animal growth via ligand-regulated GHRH myogenic-injectable vectors. FASEB J 2002; 16: 426-428.
32. Sarkar NN. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol 2002; 101: 113-120.
33. Roscilli G et al. Long-term and tight control of gene expression in mouse skeletal muscle by a new hybrid human transcription factor. Mol Ther 2002; 6: 653-663.
34. Eltabbakh GH, Mount SL. Tamoxifen and the female reproductive tract. Expert Opin Pharmacother 2001; 2: 1399-1413.
35. Fabian CJ, Kimler BF. Chemoprevention for high-risk women: tamoxifen and beyond. Breast J 2001; 7: 311-320.
36. Riddiford LM, Cherbas P, Truman JW. Ecdysone receptors and their biological actions. Vitam Horm 2000; 60: 1-73.
37. Graham LD. Ecdysone-controlled expression of transgenes. Expert Opin Biol Ther 2002; 2: 525-535.
38. Rastinejad F, Retinoid X. receptor and its partners in the nuclear receptor family. Curr Opin Struct Biol 2001; 11: 33-38.
39. Devarakonda S et al. Structure of the heterodimeric ecdysone receptor DNA-binding complex. EMBO J 2003; 22: 5827-5840.
40. Karns LR et al. Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts. BMC Biotechnol 2001; 1: 11.
41. Palli SR, Kapitkaya MZ, Kumar MB, Cress DE. Improved ecdysone receptor-based inducible gene regulation system. Eur J Biochem 2003; 270: 1308-1315.
42. Subbarayan V et al. R x Ralpha overexpression in cardiomyocytes causes dilated cardiomyopathy but fails to rescue myocardial hypoplasia in R x Ralpha-null fetuses. J Clin Invest 2000; 105: 387-394.
43. Hoppe UC, Marban E, Johns DC. Adenovirus-mediated inducible gene expression in vivo by a hybrid ecdysone receptor. Mol Ther 2000; 1: 159-164.
44. Hoppe UC, Marban E, Johns DC. Molecular dissection of cardiac repolarization by in vivo Kv4.3 gene transfer. J Clin Invest 2000; 105: 1077-1084.
45. Hoppe UC, Marban E, Johns DC. Distinct gene-specific mechanisms of arrhythmia revealed by cardiac gene transfer of two long QT disease genes, HERG and KCNE1. Proc Natl Acad Sci USA 2001; 98: 5335-5340.
46. Dinan L, Savchenko T, Whiting P. On the distribution of phytoecdysteroids in plants. Cell Mol Life Sci 2001; 58: 1121-1132.
47. Saez E et al. Identification of ligands and coligands for the ecdysone-regulated gene switch. Proc Natl Acad Sci USA 2000; 97: 14512-14517.
48. Kumar MB et al. A single point mutation in ecdysone receptor leads to increased ligand specificity: implications for gene switch applications. Proc Natl Acad Sci USA 2002; 99: 14710-14715.
49. Billas IML et al. Structural adaptability in the ligand-binding pocket of the ecdysone hormone receptor. Nature 2003; 426: 91-96.
50. Miller M, Bassler BL. Quorom sensing in bacteria. Annu Rev Microbiol 2001; 55: 165-199.
51. Vannini A et al. The crystal structure of the quorum sensing protein TraR bound to its autoinducer and target DNA. EMBO J 2002; 21: 4393-4401.
52. Neddermann P et al. A novel, inducible, eukaryotic gene expression system based on the quorum-sensing transcription factor TraR. EMBO Rep 2003; 4: 159-165.
53. Zhu J, Winans SC. The quorum-sensing transcriptional regulator TraR requires its cognate signaling ligand for protein folding, protease resistance, and dimerization. Proc Natl Acad Sci USA 2001; 98: 1507-1512.
54. Yates E et al. N-acylhomoserine lactones undergo lactonolysis in a pH-, temperature-, and acyl chain lenght-dependent manner during growth of Yersinia Pseudotuberculosis and Pseudomonas aeruginosa. Infect Immun 2002; 70: 5635-5646.
55. Weber W et al. Streptomyces-derived quorum-sensing systems engineered for adjustable transgene expression in mammalian cells and mice. Nucleic Acids Res 2003; 31: e71.
56. Roberts M. Resistance to tetracycline, macrolide-lincosamide-streptogramin, trimethoprim and sulfonamide drug classes. Mol Biotechnol 2002; 20: 261-284.
57. Fussenegger M et al. Streptogramin-based gene regulation systems for mammalian cells. Nat Biotechnol 2000; 18: 1203-1208.
58. Weber W et al. Macrolide-based transgene control in mammalian cells and mice. Nat Biotechnol 2002; 20: 901-907.
59. Weber W et al. Novel promoter/transactivator configurations for macrolide- and streptogramin-responsive transgene expression in mammalian cells. J Gene Med 2002; 4: 676-686.
60. Fux C et al. Novel macrolide-adjustable bidirectional expression modules for coordinated expression of two different transgenes in mice. J Gene Med 2003; 5: 1067-1079.
61. Beerli RR, Barbas CF. Engineering polydactyl zinc-finger transcription factors. Nat Biotechnol 2002; 20: 135-141.
62. Beerli RR, Schopfer U, Dreier B, CF Barbas CF. Chemically. regulated zinc finger transcription factors. J Biol Chem 2000; 275: 32617-32627.
63. Xu L et al. A versatile framework for the design of ligand-dependent, transgene-specific transcription factors. Mol Ther 2001; 3: 262-273.
64. Pollock R, Giel M, Linher K, Clackson T. Regulation of endogenous gene expression with a small-molecule dimerizer. Nat Biotechnol 2002; 20: 729-733.
65. Zerby D et al. In vivo ligand-inducible regulation of gene expression in a gutless adenoviral vector system. Hum Gene Ther 2003; 14: 749-761.
66. Crittenden M et al. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res 2003; 63: 3173-3189.
67. Ohkawa J, Taira K. Control of the functional activity of an antisense RNA by a tertacycline-responsive derivative of the human U6 snRNA promoter. Hum Gene Ther 2000; 11: 577-585.
68. Matsukura S, Jones PA, Takai D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res 2003; 31: e77.
69. Van de Wetering M et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 2003; 4: 609-615.
70. Wiznerowicz W, Trono D. Conditional suppression of cellular enes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003; 77: 8957-8961.